Barclays PLC Bei Gene, Ltd. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Barclays PLC holds 10,829 shares of BGNE stock, worth $2.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,829

Previous 10,829 -0.0%

Holding current value

$2.08 Million

Previous $2.43 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$143.93 - $224.51 $34,543 - $53,882	240 Added 2.27%	10,829 $2.43 Million
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $53,232 - $71,645	411 Added 4.04%	10,589 $1.51 Million
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $1.36 Million - $1.74 Million	9,610 Added 1691.9%	10,178 $1.59 Million
Q4 2023 Feb 15, 2024	SELL	$158.67 - $201.58 $39,667 - $50,395	-250 Reduced 30.56%	568 $102,000
Q3 2023 Nov 07, 2023	SELL	$179.87 - $225.13 $38,312 - $47,952	-213 Reduced 20.66%	818 $148,000
Q2 2023 Aug 03, 2023	BUY	$178.3 - $266.78 $167,958 - $251,306	942 Added 1058.43%	1,031 $184,000
Q1 2023 May 04, 2023	SELL	$215.53 - $274.5 $627,407 - $799,069	-2,911 Reduced 97.03%	89 $19,000
Q4 2022 Feb 13, 2023	SELL	$125.51 - $229.3 $4.73 Million - $8.64 Million	-37,690 Reduced 92.63%	3,000 $660,000
Q3 2022 Nov 03, 2022	SELL	$131.8 - $202.24 $3.57 Million - $5.48 Million	-27,090 Reduced 39.97%	40,690 $5.49 Million
Q2 2022 Aug 12, 2022	SELL	$121.11 - $216.05 $504,059 - $899,200	-4,162 Reduced 5.79%	67,780 $11 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $4.67 Million - $8.59 Million	31,864 Added 79.5%	71,942 $13.6 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $495,628 - $776,343	1,994 Added 5.24%	40,078 $10.9 Million
Q3 2021 Nov 09, 2021	BUY	$249.6 - $403.14 $1.27 Million - $2.06 Million	5,104 Added 15.48%	38,084 $13.8 Million
Q2 2021 Aug 13, 2021	BUY	$292.75 - $367.01 $1.55 Million - $1.94 Million	5,287 Added 19.09%	32,980 $11.3 Million
Q1 2021 May 13, 2021	SELL	$260.64 - $382.12 $12.6 Million - $18.5 Million	-48,424 Reduced 63.62%	27,693 $9.64 Million
Q4 2020 Feb 11, 2021	BUY	$221.31 - $316.61 $2.29 Million - $3.27 Million	10,326 Added 15.7%	76,117 $19.7 Million
Q3 2020 Nov 12, 2020	SELL	$189.18 - $286.44 $232,123 - $351,461	-1,227 Reduced 1.83%	65,791 $18.8 Million
Q2 2020 Aug 12, 2020	SELL	$123.9 - $195.41 $3.16 Million - $4.99 Million	-25,532 Reduced 27.59%	67,018 $12.6 Million
Q1 2020 May 13, 2020	BUY	$121.84 - $173.19 $2.22 Million - $3.15 Million	18,198 Added 24.48%	92,550 $11.4 Million
Q4 2019 Feb 10, 2020	BUY	$115.78 - $208.34 $1.17 Million - $2.11 Million	10,134 Added 15.78%	74,352 $12.3 Million
Q3 2019 Nov 14, 2019	SELL	$120.61 - $148.29 $297,665 - $365,979	-2,468 Reduced 3.7%	64,218 $7.86 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $7.37 Million - $9.49 Million	64,652 Added 3178.56%	66,686 $8.27 Million
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $1.01 Million - $1.24 Million	-8,194 Reduced 80.11%	2,034 $269,000
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $506,264 - $828,634	4,731 Added 86.07%	10,228 $1.44 Million
Q3 2018 Nov 14, 2018	BUY	$152.62 - $189.66 $838,036 - $1.04 Million	5,491 Added 91516.67%	5,497 $947,000
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $1.79 Million - $2.54 Million	-11,740 Reduced 99.95%	6 $1,000
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $1.14 Million - $2.07 Million	11,669 Added 15154.55%	11,746 $1.97 Million
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $371,493 - $535,444	-4,667 Reduced 98.38%	77 $8,000
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $314,005 - $490,814	4,744	4,744 $491,000

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account